LINDIS Biotech signs licensing agreement with Pharmanovia for the commercialization of catumaxomab

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Lindis Biotech GmbH announced a licensing agreement with global pharmaceutical company Pharmanovia for catumaxomab, for the treatment of malignant ascites.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Perioperative treatment with Imfinzi (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival versus chemotherapy alone, according to MATTERHORN phase III trial results. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login